The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density

Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density

October 19, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270A recent study linked the use of proton pump inhibitors to changes in bone mineral density and an increased risk of developing osteoporosis. Also, denosumab proved effective at increasing bone mineral density in osteoporosis patients on glucocorticoid therapy.

You Might Also Like
  • Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
  • Bone Mineral Density Most Important Determinant of Fracture Risk
  • Glucocorticoid Found to Increase Bone Mineral Density in Mouse Study
Also By This Author
  • Upadacitinib Promising for RA Patients

Proton Pump Inhibitor Use Linked to Bone Mineral Density
A recent cross-sectional study evaluated the association between proton pump inhibitor (PPI) use and bone mineral density (BMD) in patients referred to the Gastroenterology Department of Kashan University of Medical Sciences, Kashan, Iran.1 The researchers investigated the relationship between PPI use and BMD in 80 patients age 20–45 years old, which included 31 men and 49 women, none with a history of hip fracture.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The follow-up period was a minimum of two years. Half of the patients received a PPI and half did not. All participants had their femur and posterior–anterior spine BMD quantified by dual-energy X-ray absorptiometry. The primary endpoints were femur and lumbar spine T-scores. Secondary endpoints were femur and lumbar spine Z-scores. Multi-variate linear regression analysis was adjusted for age, sex, body mass index and serum vitamin D levels, and used to test the potential associations between PPI use and BMD.

Mean femoral T-scores were significantly different between PPI users and non-users (-0.44 ± 1.11 vs. +0.19 ± 0.95, P = 0.007). Additionally, the frequency of femoral osteoporosis and osteopenia in the PPI-users group was significantly more than in the control group (P=0.04). However, the mean femoral Z-scores, lumbar spine T-score and lumbar spine Z-score were not statistically different between the PPI-user and the PPI-non-user groups. The study’s authors concluded that PPI use in individuals without osteoporosis risk factors had an increased risk of developing femoral osteoporosis and osteopenia.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Denosumab & Glucocorticoid-Induced Osteoporosis
In late August, Amgen reported the positive results of a Phase 3 study of denosumab in glucocorticoid-treated patients.2 This 24-week, international, multi-center, randomized, double-blind, double-dummy, active-controlled, parallel-group study was conducted in adults (n=795) receiving oral glucocorticoid therapy.

The study was designed to compare the safety and efficacy of treatment with 60 mg subcutaneous denosumab given every six months with the daily use of 5 mg oral risedronate. Two patient subpopulations were evaluated: 505 patients receiving continuous glucocorticoid therapy, defined as receiving more than 7.5 mg prednisone daily or its equivalent for more than three months and planning to continue treatment for at least six months; and 290 patients who were newly initiating glucocorticoid therapy, defined as receiving more than 7.5 mg prednisone daily or its equivalent for longer than three months and planning to continue treatment for at least six months. The primary endpoint was the percentage change from baseline in lumbar spine bone mineral density at Month 12 (to assess non-inferiority). Two secondary endpoints were the percentage change from baseline in lumbar spine and total hip bone mineral density (assessing superiority) at Month 12.

Pages: 1 2 | Single Page

Filed Under: Conditions, Drug Updates Tagged With: bone mineral density (BMD), denosumab, Glucocorticoid-Induced Osteoporosis, Glucocorticoids, Osteoporosis, proton pump inhibitor (PPI)

You Might Also Like:
  • Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
  • Bone Mineral Density Most Important Determinant of Fracture Risk
  • Glucocorticoid Found to Increase Bone Mineral Density in Mouse Study
  • Women on Osteoporosis Drugs Still Need Bone Density Screenings

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.